Status:
COMPLETED
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
Lead Sponsor:
Gachon University Gil Medical Center
Conditions:
Burkitt's Lymphoma
High-grade B-cell Lymphoma
Eligibility:
All Genders
20+ years
Brief Summary
This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclass...
Detailed Description
Inclusion criteria 1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria 2. age \>20 yrs 3. received rituximab+chemotherapy as first-line treatment 4. with measurable or e...
Eligibility Criteria
Inclusion
- pathologically confirmed Burkitt's lymphoma (BL) or High grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL (BL-U) by WHO 2008 criteria
- age \>20 yrs
- received rituximab+chemotherapy as first-line treatment
- with measurable or evaluable lesion
Exclusion
- 1\. patients with BL or BL-U previously treated with rituximab
Key Trial Info
Start Date :
February 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT01809600
Start Date
February 1 2013
End Date
March 1 2014
Last Update
February 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gachon University Gil Medical Center
Incheon, South Korea, 405-760